inhibitor

• Health

Alecensa approved as first and only anaplastic lymphoma kinase inhibitor for non-small cell lung cancer

The U.S. Food and Drug Administration has approved Genentech's Alecensa (alectinib) as adjuvant treatment following tumor resection in patients with…